Arcturus Therapeutics Announces Encouraging Interim Phase 2 Results From Arct-810 In Otc Deficiency
ARCT•Interim Phase 2 results from Arct-810
Sept. 24 (Reuters) - Arcturus Therapeutics Holdings Inc ARCT.O:
- Arcturus Therapeutics announces encouraging interim Phase 2 results from Arct-810 in OTC deficiency.
- Arct-810 is generally safe and well tolerated in the ongoing Phase 2 study.
- Arcturus Therapeutics to buy Myneo to improve mRNA design quality.
Source text: ID:nBw4rjNvLa
Further company coverage: ARCT.O
